Public policy and advocacy
As a leading healthcare company, Novartis endeavors to actively participate in public policy debates affecting our business. We believe it is our responsibility to share our perspective, scientific knowledge and technical expertise and provide fact-based information to policymakers and regulatory authorities.
In our lobbying and advocacy activities – as in all other areas of our business – we are governed by our Code of Conduct. Third parties who conduct advocacy on our behalf are subject to our Third Party Code.
We strive to engage in constructive debate with government and other stakeholders to improve outcomes for patients globally, while preserving incentives for research and innovation. Much of this work is done through trade associations, which can be a powerful vehicle for raising industry standards and exchanging best practice.
Novartis Group companies maintain full-time public affairs offices in:
- Basel, Switzerland
- Brussels, Belgium
- Washington D.C., US
In many other countries where we operate, we have part- or full-time public affairs personnel. Our aim across all our offices is to monitor and assess regulatory and political decisions that may affect our business, to contribute to the policy process and to ensure consistency of action.
Political contributions are legitimate monetary or non-monetary contributions to support political organizations and candidates and their causes. All political contributions must be given in strict compliance with applicable laws, regulations, and industry codes. Political contributions must never be made with the expectation of a direct or immediate return for Novartis, and must always be made in compliance with local laws, regulations, and applicable industry codes.
Novartis is registered in the European Commission’s Register of Interest Representatives, a voluntary self-regulation system established by the European Commission. The register aims to increase transparency and is linked to a code of conduct. Novartis has committed to:
- Publish an estimate of the costs associated with direct lobbying of the EU institutions incurred by in-house lobbyists
- Subscribe to the Commission’s Code of Conduct or a comparable professional code
Novartis is also a proactive participant in the US political process, within the framework of the American legal system.
Corporations are prohibited from directly financing the campaigns of US candidates for federal office, but are allowed to form employee political action committees (PACs). The Novartis PAC is a bipartisan committee representing the Novartis Group, and supports candidates who share our views on issues important to the company.
The Novartis PAC supports candidates who:
- Understand and support the Novartis mission to discover, develop and successfully market innovative products to prevent and cure diseases, ease suffering and enhance quality of life
- Demonstrate leadership in key areas of importance to our business
- Show dedication to improving the relationship between business and government
- Have constituencies that include a Novartis facility or large employee demographic
Novartis adheres to the guidelines set forth by the United States Federal Election Commission (FEC) related to the federal campaign process.